Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 23 full-time employees. The firm is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The firm is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The firm is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The firm is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
Website: acertx.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 50.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -1 058.7%. On average the margin is decreasing steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 12 110.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 16.8% higher than minimum and 84.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued >100x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ACER
Share price, USD:  (0.0%)0.6601
year average price 0.6601  


year start price 0.6601 2024-12-06

max close price 0.6601 2024-12-06

min close price 0.6601 2024-12-06

current price 0.6601 2025-12-05
Common stocks: 14 310 244

Dividend Yield:  0.0%
EV / Sales: -6.4x
Margin (EBITDA LTM / Revenue): -1 058.7%
Fundamental value created in LTM:
Market Cap ($m): 9
Net Debt ($m): -13 838
EV (Enterprise Value): -13 829
Price to Book: -0.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-10-20CNBC

PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'

2023-09-01Zacks Investment Research

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

2023-08-31InvestorPlace

Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ACER ACER ACER ACER ACER ACER
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-20 2023-08-14 2023-05-15 2023-03-27 2022-11-14 2022-08-15
acceptedDate 2023-11-20 16:51:15 2023-08-14 16:19:37 2023-05-15 17:18:16 2023-03-27 16:11:13 2022-11-14 17:23:55 2022-08-15 17:01:26
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 371 790 0 0 0 0 0
costOfRevenue 83 805 0 0 0 0 0
grossProfit 287 985 0 0 0 0 0
grossProfitRatio 0.775 0 0 0 0 0
researchAndDevelopmentExpenses 2M 1M 2M 3M 3M 3M
generalAndAdministrativeExpenses 0 3M 3M 3M 3M 4M
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 3M 3M 3M 3M 4M
otherExpenses 7M 0 -577 225 -229 500 0 -200 129
operatingExpenses 13M 4M 5M 5M 5M 7M
costAndExpenses 13M 4M 5M 5M 5M 7M
interestIncome 0 0 0 0 0 0
interestExpense -133 000 0 -286 537M 82 001 19 431 0
depreciationAndAmortization -39 586 9929 15 547 4M -321 089 18 190
ebitda -13M -9M 5M -1M -6M -3M
ebitdaratio -34.638 0 0 0 0 0
operatingIncome -13M -4M 5M -5M -5M -7M
operatingIncomeRatio -34.638 0 0 0 0 0
totalOtherIncomeExpensesNet -2M -4M -22M -4M 232 105 5M
incomeBeforeTax -15M -8M -16M -9M -5M -3M
incomeBeforeTaxRatio -39.622 0 0 0 0 0
incomeTaxExpense 0 0 11 577 942M 2M -19 431 0
netIncome -15M -8M -11 577 958M -11M -5M -3M
netIncomeRatio -39.622 0 0 0 0 0
eps -0.6 -0.33 -548 376 -0.65 -0.31 -0.17
epsdiluted -0.6 -0.33 -548 376 -0.65 -0.31 -0.17
weightedAverageShsOut 24M 24M 21M 17M 16M 15M
weightedAverageShsOutDil 24M 24M 21M 17M 16M 15M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ACER ACER ACER ACER ACER ACER
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-20 2023-08-14 2023-05-15 2023-03-27 2022-11-14 2022-08-15
acceptedDate 2023-11-20 16:51:15 2023-08-14 16:19:37 2023-05-15 17:18:16 2023-03-27 16:11:13 2022-11-14 17:23:55 2022-08-15 17:01:26
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 594 659 2M 6M 2M 6M 14M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 594 659 2M 6M 2M 6M 14M
netReceivables 0 0 800 777 0 0 0
inventory 5M 5M 412 038 0 0 0
otherCurrentAssets 343 556 597 977 14 638 20 188 5436 731 379
totalCurrentAssets 6M 7M 8M 4M 7M 15M
propertyPlantEquipmentNet 40 976 54 273 202 097 214 578 92 502 101 582
goodwill 8M 8M 8M 8M 8M 8M
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 8M 8M 8M 8M 8M 8M
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 173 010 194 725 215 302 245 683 280 695 292 918
totalNonCurrentAssets 8M 8M 8M 8M 8M 8M
otherAssets 0 0 0 0 0 0
totalAssets 14M 15M 16M 12M 15M 23M
accountPayables 7M 6M 2M 4M 5M 3M
shortTermDebt 18M 32M 29M 2M 2M 2M
taxPayables 0 0 0 0 0 0
deferredRevenue 0 5M 0 0 0 0
otherCurrentLiabilities 37M 6M 8M 13M 15M 12M
totalCurrentLiabilities 62M 43M 38M 19M 21M 17M
longTermDebt 0 100 836 123 509 9M 7M 7M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 -122M 0 0
otherNonCurrentLiabilities 77M 4M 4M 122M 540 025 8M
totalNonCurrentLiabilities 77M 4M 4M 9M 7M 15M
otherLiabilities -77M 0 0 0 0 0
capitalLeaseObligations 0 0 228 332 249 590 167 321 166 134
totalLiabilities 62M 48M 42M 28M 28M 32M
preferredStock 0 0 0 0 0 0
commonStock 2446 2446 2342 1962 1637 1567
retainedEarnings -180M -165M -157M -141M -131M -126M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 132M 132M 131M 124M 119M 118M
totalStockholdersEquity -48M -33M -26M -17M -12M -9M
totalEquity -48M -33M -26M -17M -12M -9M
totalLiabilitiesAndStockholdersEquity 14 002M 15M 16M 12M 15M 23M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 14 002M 15M 16M 12M 15M 23M
totalInvestments 0 0 0 0 0 0
totalDebt 18M 32M 29M 12M 8M 9M
netDebt 18M 31M 22M 10M 2M -6M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ACER ACER ACER ACER ACER ACER
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2023-11-20 2023-08-14 2023-05-15 2023-03-27 2022-11-14 2022-08-15
acceptedDate 2023-11-20 16:51:15 2023-08-14 16:19:37 2023-05-15 17:18:16 2023-03-27 16:11:13 2022-11-14 17:23:55 2022-08-15 17:01:26
calendarYear 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -16M -8M -16M -9M -5M -3M
depreciationAndAmortization 0 9929 15 547 13 254 13 985 18 190
deferredIncomeTax 0 487 895 0 0 0 0
stockBasedCompensation 0 259 903 285 509 445 510 460 115 460 777
changeInWorkingCapital 0 -977 734 -4M -3M -4M -3M
accountsReceivables 0 1M 0 -5M 0 0
inventory 0 -4M -412 038 0 0 0
accountsPayables 0 4M -2M -874 233 1M 1M
otherWorkingCapital 0 -2M -1M 2M -6M -5M
otherNonCashItems 285 509 3M 11M 4M -202 150 0
netCashProvidedByOperatingActivities -16M -6M -9M -8M -9M -10M
investmentsInPropertyPlantAndEquipment 0 0 -3066 -135 330 -4905 -2005
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 -3066 -135 330 -4905 -2005
debtRepayment 0 0 -98 655 -724 929 0 0
commonStockIssued 6M 347 613 6M 4M 1M 4M
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 6M 677 628 7M 724 929 0 -1
netCashUsedProvidedByFinancingActivities 6M 677 628 13M 4M 1M 4M
effectOfForexChangesOnCash 0 0 0 0 0 0
netChangeInCash -10M -5M 4M -4M -8M -6M
cashAtEndOfPeriod -10M 2M 6M 2M 6M 14M
cashAtBeginningOfPeriod 0 6M 2M 6M 14M 21M
operatingCashFlow -16M -6M -9M -8M -9M -10M
capitalExpenditure 0 0 -3066 -135 330 -4905 -2005
freeCashFlow -16M -6M -9M -8M -9M -10M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2023-11-02 12:30 ET
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
2023-08-31 11:30 ET
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
2023-08-30 20:05 ET
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
2023-08-14 20:05 ET
Acer Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-06-26 12:30 ET
Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder
2023-05-15 21:10 ET
Acer Therapeutics Reports Q1 2023 Financial Results and Provides Corporate Update
2023-05-01 12:30 ET
Acer Therapeutics Announces OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
2023-03-27 20:01 ET
Acer Therapeutics Reports Q4 and Full Year 2022 Financial Results and Provides Corporate Update
2023-03-22 12:30 ET
Acer Therapeutics Announces Data Presented at Society for Inherited Metabolic Disorders Annual Meeting Identifying Preferred Urea Cycle Disorder Treatment Attributes
2023-03-22 12:00 ET
Acer Therapeutics Announces $2.675 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-03-17 12:30 ET
Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a Trial
2023-03-15 12:30 ET
Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides OLPRUVA™ Program Update
2023-02-13 13:30 ET
Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
2023-01-31 13:00 ET
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
2023-01-09 13:30 ET
Acer Therapeutics Highlights Key 2022 Achievements and Pipeline Advancements, and Provides Anticipated 2023 Milestones
2023-01-05 13:30 ET
Acer Therapeutics Announces Initiation of Two Investigator-Sponsored Trials of ACER-801 (Osanetant) in Men with Adenocarcinoma of the Prostate
2022-12-29 13:30 ET
Acer Therapeutics Compliant with All Nasdaq Listing Criteria
2022-12-27 13:30 ET
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders
2022-11-30 13:30 ET
Acer Therapeutics Announces $1.5M Private Placement
2022-11-14 22:08 ET
Acer Therapeutics Reports Q3 2022 Financial Results and Provides Corporate Update
2022-10-26 12:30 ET
Acer Therapeutics Receives Notice of Allowance of Key US Patent Application Covering EDSIVO™ (celiprolol)
2022-10-18 20:05 ET
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
2022-10-06 12:30 ET
Acer Therapeutics Announces University of North Carolina Receives Department of Defense Grant to Support the Proposed Investigator Sponsored OASIS Trial of ACER-801 (Osanetant) to Reduce the Frequency and Severity of Post-Traumatic Stress Disorder
2022-10-05 12:30 ET
Acer Therapeutics Announces Expansion of ACER-801 (osanetant) Development Indications to Include Post-Traumatic Stress Disorder
2022-10-03 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate
2022-08-23 12:30 ET
Acer Therapeutics to Participate in August and September 2022 Investor Conferences
2022-08-15 20:00 ET
Acer Therapeutics Reports Q2 2022 Financial Results and Provides Corporate Update
2022-08-12 12:30 ET
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
2022-07-28 12:33 ET
Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease
2022-07-28 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
2022-07-18 12:30 ET
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
2022-07-08 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form
2022-06-27 12:30 ET
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
2022-06-21 12:32 ET
Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
2022-06-21 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001
2022-06-07 12:30 ET
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
2022-05-16 20:01 ET
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
2022-05-09 12:30 ET
Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO™ (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients
2022-05-06 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
2022-05-06 05:40 ET
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
2022-05-05 12:30 ET
Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
2022-04-12 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
2022-04-12 05:20 ET
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
2022-04-04 12:30 ET
Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome
2022-03-31 12:30 ET
Acer Therapeutics Regains Compliance with Nasdaq Listing Standard
2022-03-30 12:30 ET
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
2022-03-28 11:00 ET
SWK Holdings Corporation Announces Financial Results for Fourth Quarter and Full-Year 2021
2022-03-07 11:15 ET
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities
2022-03-02 22:18 ET
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
2022-02-22 13:30 ET
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer
2022-02-01 13:30 ET
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
2022-01-27 13:30 ET
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
2021-12-22 13:30 ET
Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences
2021-12-09 13:30 ET
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms
2021-11-19 22:00 ET
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
2021-10-26 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation
2021-10-07 12:30 ET
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation
2021-10-06 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application for ACER-001 to Treat Urea Cycle Disorders
2021-08-30 12:30 ET
Acer Therapeutics to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
2021-08-10 20:05 ET
Acer Therapeutics Reports Q2 2021 Financial Results and Provides Corporate Update
2021-08-09 12:30 ET
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
2021-08-09 05:30 ET
RELIEF THERAPEUTICS Holdings AG: Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders
2021-07-08 15:20 ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
2021-06-23 13:35 ET
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
2021-06-10 12:30 ET
Acer Therapeutics Plans Clinical Trial for EDSIVO™ (celiprolol) Following Type B FDA Meeting
2021-05-25 12:30 ET
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
2021-05-17 20:01 ET
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update
2021-03-29 12:30 ET
Acer Therapeutics to Participate in Needham Virtual Healthcare Conference
2021-03-25 20:05 ET
Notice of Settlement of Derivative Suits
2021-03-22 12:30 ET
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
2021-03-01 21:05 ET
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
2021-03-01 13:30 ET
Acer Therapeutics to Participate in March Virtual Investor Conferences
2021-02-11 13:30 ET
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
2020-12-22 13:30 ET
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
2020-12-17 13:30 ET
Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden
2020-11-10 21:05 ET
Acer Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2020-10-01 12:30 ET
Acer Therapeutics to Present at the Virtual BIO Investor Forum Digital
2020-08-25 13:00 ET
Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
2020-08-13 20:01 ET
Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-08 20:01 ET
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
2020-05-14 20:01 ET
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-11 20:05 ET
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
2020-04-30 20:01 ET
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital
2020-03-18 20:05 ET
Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New Drugs
2020-03-18 20:05 ET
Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2020-02-24 21:05 ET
Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®
2019-12-16 21:05 ET
Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
2019-11-13 21:05 ET
Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-10-28 20:01 ET
Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
2019-08-29 16:27 ET
ACER IMMINENT DEADLINE: Rosen, A Top Ranked Law Firm, Announces Filing of Securities Class Action Lawsuit Against Acer Therapeutics Inc.; Important August 30th Deadline - ACER
2019-08-27 14:00 ET
FINAL DEADLINE - Acer Therapeutics Inc. (ACER)  - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019
2019-08-02 18:54 ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact the Firm
2019-07-26 21:08 ET
Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation
2019-07-17 02:05 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acer Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ACER
2019-07-12 22:59 ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Acer Therapeutics, Inc. - ACER
2019-07-03 21:54 ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Acer Therapeutics Inc. To Contact The Firm
2019-05-23 13:06 ET
Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE
2019-03-13 15:17 ET
-- Acer Therapeutics to Participate in Upcoming Investor Conferences
2019-03-13 12:30 ET
Acer Therapeutics to Participate in Upcoming Investor Conferences
2019-03-07 21:01 ET
Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

SEC forms

Show financial reports only

SEC form 10
2023-11-20 16:51 ET
Acer Therapeutics reported for 2023 q3
SEC form 10
2023-11-20 00:00 ET
Acer Therapeutics reported for 2023 q3
SEC form 10
2023-08-14 16:19 ET
Acer Therapeutics reported for 2023 q2
SEC form 6
2023-08-14 16:09 ET
Acer Therapeutics reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Acer Therapeutics reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Acer Therapeutics reported for 2023 q2
SEC form 6
2023-06-26 09:00 ET
Acer Therapeutics published news for 2023 q1
SEC form 10
2023-05-15 17:18 ET
Acer Therapeutics reported for 2023 q1
SEC form 6
2023-05-15 17:10 ET
Acer Therapeutics reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Acer Therapeutics reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Acer Therapeutics reported for 2023 q1
SEC form 6
2023-05-03 17:33 ET
Acer Therapeutics published news for 2023 q1
SEC form 6
2023-05-01 09:00 ET
Acer Therapeutics published news for 2023 q1
SEC form 6
2023-04-27 06:06 ET
Acer Therapeutics published news for 2023 q1
SEC form 6
2023-04-14 16:25 ET
Acer Therapeutics published news for 2023 q1
SEC form 10
2023-03-27 16:11 ET
Acer Therapeutics reported for 2022 q4
SEC form 6
2023-03-27 16:03 ET
Acer Therapeutics reported for 2022 q4
SEC form 8
2023-03-27 00:00 ET
Acer Therapeutics reported for 2022 q4
SEC form 10
2023-03-27 00:00 ET
Acer Therapeutics reported for 2022 q4
SEC form 6
2023-03-22 16:01 ET
Acer Therapeutics published news for 2022 q4
SEC form 6
2023-03-17 09:00 ET
Acer Therapeutics published news for 2022 q4
SEC form 6
2023-03-15 09:00 ET
Acer Therapeutics published news for 2022 q4
SEC form 10
2022-11-14 00:00 ET
Acer Therapeutics reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Acer Therapeutics reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Acer Therapeutics published news for 2022 q3
SEC form 8
2022-08-15 00:00 ET
Acer Therapeutics reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Acer Therapeutics reported for 2022 q2
SEC form 8
2022-05-16 00:00 ET
Acer Therapeutics reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Acer Therapeutics reported for 2022 q1
SEC form 8
2022-03-02 00:00 ET
Acer Therapeutics published news for 2021 q4
SEC form 10
2022-03-02 00:00 ET
Acer Therapeutics published news for 2021 q4
SEC form 8
2021-11-19 00:00 ET
Acer Therapeutics published news for 2021 q3
SEC form 10
2021-11-19 00:00 ET
Acer Therapeutics published news for 2021 q3
SEC form 8
2021-11-16 00:00 ET
Acer Therapeutics published news for 2021 q3
SEC form 10
2021-08-10 00:00 ET
Acer Therapeutics published news for 2021 q2
SEC form 10
2021-05-17 00:00 ET
Acer Therapeutics published news for 2021 q1